EUDA Health Holdings Full Year 2024 Earnings: US$0.54 loss per share (vs US$0.37 loss in FY 2023)
EUDA Health Holdings ( NASDAQ:EUDA ) Full Year 2024 Results Key Financial Results Revenue: US$4.01m (up 8.2% from FY...
| Ticker |
EUDA
|
| CIK | 0001847846 |
| SIC | 8000 |
| Sector | Services |
| Industry Category | Healthcare |
| Industry Group | Services – Health |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
EUDA Health Holdings Full Year 2024 Earnings: US$0.54 loss per share (vs US$0.37 loss in FY 2023)EUDA Health Holdings ( NASDAQ:EUDA ) Full Year 2024 Results Key Financial Results Revenue: US$4.01m (up 8.2% from FY... EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and MalaysiaSINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerativ EUDA Health Holdings Limited (NASDAQ:EUDA) stock most popular amongst retail investors who own 49%, while private companies hold 27%Key Insights The considerable ownership by retail investors in EUDA Health Holdings indicates that they collectively... EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation- Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”), a prominent player in stem cell therapies and regenerative medicin NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to ScheduleMIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ: NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Jonathan Javitt, M |